Clinical outcomes and management of patients with concomitant primary sclerosing cholangitis and inflammatory bowel disease

被引：0
|
作者：
Wu, K. [1 ,2 ]
Connell, W. [2 ]
Bell, S. [2 ]
Kamm, M. [2 ]
Wright, E. [2 ]
Lust, M. [2 ]
Brown, S. [2 ]
Thompson, A. [2 ]
Ding, N. [2 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] St Vincents Hosp Melbourne, Dept Gastroenterol, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [1] Effectiveness of Vedolizumab in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis
    Santiago, Priscila
    Robateau, Anthony
    Lopdrup, Rachel G.
    Neto, Manuel B. Braga
    Raffals, Laura
    Eaton, John
    Ramos, Guilherme
    Loftus, Edward V.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S688 - S689
  • [2] ASSESSING OUTCOMES OF PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE
    Garg, Kanika
    Eswaran, Sheila L.
    [J]. HEPATOLOGY, 2021, 74 : 745A - 746A
  • [3] Risk of colorectal cancer in patients with primary sclerosing cholangitis and concomitant inflammatory bowel disease compared with primary sclerosing cholangitis only
    Das, Taranika Sarkar
    Ho, Kimberly
    Udaikumar, Jahnavi
    Chen, Bryan
    Delau, Olivia
    Shaukat, Aasma
    Jacobson, Ira
    Sarwar, Raiya
    [J]. HEPATOLOGY RESEARCH, 2024, 54 (09) : 807 - 816
  • [4] CLINICAL AND TRANSLATIONAL OUTCOMES IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE RECEIVING VEDOLIZUMAB
    Williamson, Kate D.
    Slevin, Stephanie
    Willberg, Christian
    Chapman, Roger W.
    Klenerman, Paul
    Keshav, Satish
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S1186 - S1187
  • [5] RACE INFLUENCES CLINICAL OUTCOMES OF PATIENTS WTIH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE
    Haj, Mona
    Bickford, Megan M.
    Forster, Erin M.
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S444 - S445
  • [6] Clinical and translational outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease receiving vedolizumab
    Williamson, K. D.
    Slevin, S.
    Willberg, C.
    Chapman, R.
    Klenerman, P.
    Keshav, S.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S544 - S545
  • [7] Inflammatory Bowel Disease Is Associated With Poor Outcomes of Patients With Primary Sclerosing Cholangitis
    Ngu, Jing Hieng
    Gearry, Richard Blair
    Wright, Andrew Jeffrey
    Stedman, Catherine Ann Malcolm
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (12) : 1092 - 1097
  • [8] Clinical features of primary sclerosing cholangitis and inflammatory bowel disease
    程小韵
    [J]. China Medical Abstracts (Internal Medicine), 2023, 40 (03) : 175 - 175
  • [9] CLINICAL PRESENTATION AND OUTCOMES OF PRIMARY SCLEROSING CHOLANGITIS AND AUTOIMMUNE HEPATITIS IN INFLAMMATORY BOWEL DISEASE
    Martins, Camilla A.
    Caon, Ana Elisa R.
    Cruz, Marilia G.
    Barros, Luisa L.
    Carlos, Alexandre
    Azevedo, Matheus
    Queiroz, Natalia S.
    Milani, Luciane R.
    Terrabuio, Debora R.
    Cancado, Eduardo Luiz Rachid
    Damiao, Aderson O.
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S732 - S733
  • [10] Dysregulation of antioxidant responses in patients diagnosed with concomitant Primary Sclerosing Cholangitis/Inflammatory Bowel Disease
    Colin, Shearn T.
    David, Orlicky J.
    Dennis, Petersen R.
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2018, 104 (01) : 1 - 8
12345